{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:25:01Z","timestamp":1791397501530,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas Pharma Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tapering or stopping biological disease-modifying anti-rheumatic drugs has been proposed for patients with rheumatoid arthritis (RA) in remission, but it frequently results in high rates of recurrence. This study evaluates the efficacy and safety of tacrolimus (TAC) as maintenance therapy in patients with established RA in remission after receiving combination therapy with tumor necrosis factor inhibitor (TNFi) and methotrexate (MTX).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This 24-week, prospective, open-label trial included patients who received TNFi and MTX at stable doses for \u226524\u2009weeks and had low disease activity (LDA), measured by Disease Activity Score-28 for \u226512\u2009weeks. Patients selected one of two arms: maintenance (TNFi plus MTX) or switched (TAC plus MTX). The primary outcome was the difference in the proportion of patients maintaining LDA at week 24, which was assessed using a logistic regression model. Adverse events were monitored throughout the study period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In efficacy analysis, 80 and 34 patients were included in the maintenance and switched arms, respectively. At week 24, LDA was maintained in 99% and 91% of patients in the maintenance and switched arms, respectively (odds ratio, 0.14; 95% confidence interval, 0.01\u20131.59). Drug-related adverse effects tended to be more common in the switched arm than in the maintenance arm (20.9% versus 7.1%, respectively) but were well-tolerated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This controlled study tested a novel treatment strategy of switching from TNFi to TAC in RA patients with sustained LDA, and the findings suggested that TNFi can be replaced with TAC in most patients without the patients experiencing flare-ups for at least 24\u2009weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Korea CDC CRIS, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/cris.nih.go.kr\/cris\/en\/search\/search_result_st01.jsp?seq=18733\">KCT0005868<\/jats:ext-link>. Registered 4 February 2021\u2014retrospectively registered<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02566-z","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T03:27:54Z","timestamp":1625714874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Switching from TNF\u03b1 inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNF\u03b1 inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Sang Youn","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hee","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Jo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-In","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Bum","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8224-8496","authenticated-orcid":false,"given":"Wan-Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"issue":"9285","key":"2566_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903\u201311. https:\/\/doi.org\/10.1016\/S0140-6736(01)06075-5.","journal-title":"Lancet"},{"issue":"2","key":"2566_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.10083","volume":"46","author":"RB Landew\u00e9","year":"2002","unstructured":"Landew\u00e9 RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347\u201356. https:\/\/doi.org\/10.1002\/art.10083.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2566_CR3","doi-asserted-by":"publisher","first-page":"R122","DOI":"10.1186\/ar3060","volume":"12","author":"V Rantalaiho","year":"2010","unstructured":"Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, J\u00e4rvenp\u00e4\u00e4 S, Hannonen P, et al. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther. 2010;12(3):R122. https:\/\/doi.org\/10.1186\/ar3060.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2566_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207524.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2566_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrrheum.2011.201","volume":"8","author":"GR Burmester","year":"2012","unstructured":"Burmester GR. RA in 2011: advances in diagnosis, treatment and definition of remission. Nat Rev Rheumatol. 2012;8(2):65\u20136. https:\/\/doi.org\/10.1038\/nrrheum.2011.201.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"2566_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/intimm\/dxs047","volume":"24","author":"S Bl\u00fcml","year":"2012","unstructured":"Bl\u00fcml S, Scheinecker C, Smolen JS, Redlich K. Targeting TNF receptors in rheumatoid arthritis. Int Immunol. 2012;24(5):275\u201381. https:\/\/doi.org\/10.1093\/intimm\/dxs047.","journal-title":"Int Immunol"},{"issue":"9410","key":"2566_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(04)15640-7.","journal-title":"Lancet"},{"issue":"22","key":"2566_CR8","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594\u2013602. https:\/\/doi.org\/10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"issue":"5","key":"2566_CR9","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50(5):1400\u201311. https:\/\/doi.org\/10.1002\/art.20217.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2566_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2566_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","volume":"12","author":"F Atzeni","year":"2012","unstructured":"Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2012.06.008.","journal-title":"Autoimmun Rev"},{"issue":"19","key":"2566_CR12","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275\u201385. https:\/\/doi.org\/10.1001\/jama.295.19.2275.","journal-title":"JAMA"},{"issue":"11","key":"2566_CR13","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","volume":"70","author":"X Mariette","year":"2011","unstructured":"Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70(11):1895\u2013904. https:\/\/doi.org\/10.1136\/ard.2010.149419.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2566_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.berh.2011.10.001","volume":"25","author":"B Fautrel","year":"2011","unstructured":"Fautrel B, Verstappen SM, Boonen A. Economic consequences and potential benefits. Best Pract Res Clin Rheumatol. 2011;25(4):607\u201324. https:\/\/doi.org\/10.1016\/j.berh.2011.10.001.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"2566_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/acr.23315","volume":"70","author":"M Ghiti Moghadam","year":"2018","unstructured":"Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, et al. Impact of stopping tumor necrosis factor inhibitors on rheumatoid arthritis patients\u2019 burden of disease. Arthritis Care Res. 2018;70(4):516\u201324. https:\/\/doi.org\/10.1002\/acr.23315.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"2566_CR16","doi-asserted-by":"publisher","first-page":"e000133","DOI":"10.1136\/rmdopen-2015-000133","volume":"2","author":"K Chatzidionysiou","year":"2016","unstructured":"Chatzidionysiou K, Turesson C, Teleman A, Knight A, Lindqvist E, Larsson P, et al. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission. RMD Open. 2016;2(1):e000133. https:\/\/doi.org\/10.1136\/rmdopen-2015-000133.","journal-title":"RMD Open"},{"issue":"8","key":"2566_CR17","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, et al. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheum. 2016;68(8):1810\u20137. https:\/\/doi.org\/10.1002\/art.39626.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2566_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003495-199754060-00009","volume":"54","author":"CM Spencer","year":"1997","unstructured":"Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs. 1997;54(6):925\u201375. https:\/\/doi.org\/10.2165\/00003495-199754060-00009.","journal-title":"Drugs"},{"issue":"3","key":"2566_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357\u201375. https:\/\/doi.org\/10.1111\/1756-185X.13513.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"2566_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/1756-185X.13521","volume":"22","author":"K Shin","year":"2019","unstructured":"Shin K, Baek HJ, Kang YM, Cha HS, Kang SW, Park SH, et al. Efficacy and safety of add-on tacrolimus versus leflunomide in rheumatoid arthritis patients with inadequate response to methotrexate. Int J Rheum Dis. 2019;22(6):1115\u201322. https:\/\/doi.org\/10.1111\/1756-185X.13521.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2566_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4078\/jrd.2019.26.1.20","volume":"26","author":"DH Sheen","year":"2019","unstructured":"Sheen DH, Hong SJ, Lee SH, Lee HS, Chung WT, Jiang H, et al. Effectiveness and safety of tacrolimus in patients with active rheumatoid arthritis with inadequate response to disease-modifying anti-rheumatic drugs: the TREASURE study. J Rheum Dis. 2019;26(1):20\u201330. https:\/\/doi.org\/10.4078\/jrd.2019.26.1.20.","journal-title":"J Rheum Dis"},{"issue":"3","key":"2566_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/BOR.0b013e328099af80","volume":"19","author":"K Kitahara","year":"2007","unstructured":"Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19(3):238\u201345. https:\/\/doi.org\/10.1097\/BOR.0b013e328099af80.","journal-title":"Curr Opin Rheumatol"},{"key":"2566_CR23","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fimmu.2020.00195","volume":"11","author":"YJ Park","year":"2020","unstructured":"Park YJ, Yoo SA, Kim M, Kim WU. The role of calcium-calcineurin-NFAT signaling pathway in health and autoimmune diseases. Front Immunol. 2020;11:195. https:\/\/doi.org\/10.3389\/fimmu.2020.00195.","journal-title":"Front Immunol"},{"issue":"11","key":"2566_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/resp.13365","volume":"23","author":"Y Yamano","year":"2018","unstructured":"Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology. 2018;23(11):1041\u20138. https:\/\/doi.org\/10.1111\/resp.13365.","journal-title":"Respirology"},{"issue":"11","key":"2566_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.3899\/jrheum.161217","volume":"44","author":"N Sharma","year":"2017","unstructured":"Sharma N, Putman MS, Vij R, Strek ME, Dua A. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol. 2017;44(11):1612\u20138. https:\/\/doi.org\/10.3899\/jrheum.161217.","journal-title":"J Rheumatol"},{"issue":"8","key":"2566_CR26","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/art.21240","volume":"52","author":"MR Wilkes","year":"2005","unstructured":"Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439\u201346. https:\/\/doi.org\/10.1002\/art.21240.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2566_CR27","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3899\/jrheum.141520","volume":"42","author":"TM Kuijper","year":"2015","unstructured":"Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, Hazes JM, Luime JJ. Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stopping synthetic or biologic DMARD: a systematic review. J Rheumatol. 2015;42(11):2012\u201322. https:\/\/doi.org\/10.3899\/jrheum.141520.","journal-title":"J Rheumatol"},{"issue":"11","key":"2566_CR28","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/annrheumdis-2011-200945","volume":"71","author":"A van der Maas","year":"2012","unstructured":"van der Maas A, Kievit W, van den Bemt BJ, van den Hoogen FH, van Riel PL, den Broeder AA. Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis. 2012;71(11):1849\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200945.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2566_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","volume":"75","author":"J Haschka","year":"2016","unstructured":"Haschka J, Englbrecht M, Hueber AJ, Manger B, Kleyer A, Reiser M, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45\u201351. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206439.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2566_CR30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","volume":"77","author":"MJ l\u2019Ami","year":"2018","unstructured":"l\u2019Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77(4):484\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211781.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2566_CR31","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/annrheumdis-2017-211169","volume":"76","author":"CA Bouman","year":"2017","unstructured":"Bouman CA, van Herwaarden N, van den Hoogen FH, Fransen J, van Vollenhoven RF, Bijlsma JW, et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial. Ann Rheum Dis. 2017;76(10):1716\u201322. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211169.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2566_CR32","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381. https:\/\/doi.org\/10.1002\/art.27584.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"2566_CR33","first-page":"1976","volume":"22","author":"R Rau","year":"1995","unstructured":"Rau R, Herborn G. A modified version of Larsen\u2019s scoring method to assess radiologic changes in rheumatoid arthritis. J Rheumatol. 1995;22(10):1976\u201382.","journal-title":"J Rheumatol"},{"issue":"1","key":"2566_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","volume":"52","author":"J Listing","year":"2013","unstructured":"Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/kes305.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"2566_CR35","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1002\/art.40196","volume":"69","author":"ME Weinblatt","year":"2017","unstructured":"Weinblatt ME, Bingham CO 3rd, Burmester GR, Bykerk VP, Furst DE, Mariette X, et al. A phase III study evaluating continuation, tapering, and withdrawal of certolizumab pegol after one year of therapy in patients with early rheumatoid arthritis. Arthritis Rheum. 2017;69(10):1937\u201348. https:\/\/doi.org\/10.1002\/art.40196.","journal-title":"Arthritis Rheum"},{"issue":"9870","key":"2566_CR36","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","volume":"381","author":"JS Smolen","year":"2013","unstructured":"Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet. 2013;381(9870):918\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(12)61811-X.","journal-title":"Lancet"},{"issue":"2","key":"2566_CR37","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","volume":"74","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis. 2015;74(2):389\u201395. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204016.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2566_CR38","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/rheumatology\/kex315","volume":"56","author":"F Ibrahim","year":"2017","unstructured":"Ibrahim F, Lorente-C\u00e1novas B, Dor\u00e9 CJ, Bosworth A, Ma MH, Galloway JB, et al. Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders? Rheumatology (Oxford). 2017;56(11):2004\u201314. https:\/\/doi.org\/10.1093\/rheumatology\/kex315.","journal-title":"Rheumatology (Oxford)"},{"issue":"47","key":"2566_CR39","doi-asserted-by":"publisher","first-page":"e292","DOI":"10.3346\/jkms.2018.33.e292","volume":"33","author":"J Kang","year":"2018","unstructured":"Kang J, Jeong DH, Han M, Yang SK, Byeon JS, Ye BD, et al. Incidence of active tuberculosis within one year after tumor necrosis factor inhibitor treatment according to latent tuberculosis infection status in patients with inflammatory bowel disease. J Korean Med Sci. 2018;33(47):e292. https:\/\/doi.org\/10.3346\/jkms.2018.33.e292.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"2566_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4078\/jrd.2020.27.3.159","volume":"27","author":"Y Kim","year":"2020","unstructured":"Kim Y, Kim G-T, Suh YS, Kim H-O, Lee H-N, Lee S-G. The impact of the amendment of the Korean national health insurance reimbursement criteria for anti-tumor necrosis factor- \u03b1 agents on treatment pattern, clinical response and persistence in patients with rheumatoid arthritis. J Rheum Dis. 2020;27(3):159\u201367. https:\/\/doi.org\/10.4078\/jrd.2020.27.3.159.","journal-title":"J Rheum Dis"},{"key":"2566_CR41","doi-asserted-by":"publisher","unstructured":"Berkhout LC, l\u2019Ami MJ, Ruwaard J, Hart MH, Heer PO, Bloem K, et al. Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay. Sci Transl Med. 2019;11(477). https:\/\/doi.org\/10.1126\/scitranslmed.aat3356.","DOI":"10.1126\/scitranslmed.aat3356"},{"issue":"9","key":"2566_CR42","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1073\/pnas.1011774108","volume":"108","author":"A Hess","year":"2011","unstructured":"Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-\u03b1 rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 2011;108(9):3731\u20136. https:\/\/doi.org\/10.1073\/pnas.1011774108.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2566_CR43","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1002\/art.11363","volume":"48","author":"DE Yocum","year":"2003","unstructured":"Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. 2003;48(12):3328\u201337. https:\/\/doi.org\/10.1002\/art.11363.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2566_CR44","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/rheumatology\/keh155","volume":"43","author":"DE Yocum","year":"2004","unstructured":"Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford). 2004;43(8):992\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keh155.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2566_CR45","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jbspin.2008.11.009","volume":"76","author":"O Brocq","year":"2009","unstructured":"Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, et al. Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine. 2009;76(4):350\u20135. https:\/\/doi.org\/10.1016\/j.jbspin.2008.11.009.","journal-title":"Joint Bone Spine"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02566-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02566-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T03:28:07Z","timestamp":1625714887000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02566-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2566"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02566-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"8 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Before study initiation, the study protocol was approved by the Institutional Review Board of each participating institution as follows: Seoul St. Mary\u2019s hospital, Suwon St. Vincent hospital, and Yeouido St. Mary\u2019s hospital (XC12MIMV0055K); CHA Bundang Medical Center (BD2012-086D); Chonnam National University hospital (CNUH-2013-062); Kyung Hee University Hospital at Gangdong (KHNMC IRB 2012-024); Korea University Ansan Hospital (AS13022-002); Ewha Woman\u2019s University MokDong Hospital (EUMC 2015-01-045-002); and Hanyang University Seoul Hospital (HYUH 2015-02-007-001). All subjects provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}